Phase 1b/2 pepinemab/PDAC study update to be presented on September 29 at special AACR meeting New ActivMAb® application to be reviewed on September 28 at CHI s 20th Annual Discovery on.
27.09.2023 - Phase 1b/2 pepinemab/PDAC study update to be presented on September 29 at special AACR meeting New ActivMAb application to be reviewed on September 28 at CHI s 20th Annual Discovery on Target (DOT) conference ROCHESTER, N.Y., Sept. . Seite 1